The DOI matches its Crossref record; 48 of the 49 references it cites were found in a registry or an index.
CB1 cannabinoid receptors mediate anxiolytic effects: convergent genetic and pharmacological evidence with CB1-specific agents
Abstract
Cannabinoids are known to modulate GABAergic and glutamatergic transmission in cortical areas, the former via CB1 and the latter via a novel receptor. Pharmacological data demonstrate that several widely used cannabinoid ligands bind to both receptors, which may explain the inconsistencies in their behavioural effects. Earlier we showed that the cannabinoid antagonist SR-141716A affected behaviour in both CB1 knockout and wild-type animals, and its effect (anxiolysis) was different from that of CB1 gene disruption (anxiogenesis). In the present experiments, we studied the effects of the CB1 antagonist AM-251, and the cannabinoid agonist WIN-55,212-2 in wild-type as well as in CB1 knockout mice. CB1 knockout mice showed higher scores of anxiety-like behaviour than the wild-type animals in the elevated plus-maze. Selective blockade of CB1 receptors by AM-251 (0.3, 1 and 3 mg/kg) increased anxiety-like behaviour dose-dependently in the wild-type mice but had no effect in the knockouts. In wild types, the cannabinoid agonist WIN-55,212-2 (1 and 3 mg/kg) caused a decrease in anxiety-like behaviour, which was abolished by the CB1-selective antagonist AM-251 (3 mg/kg). The same agonist did not change plus-maze behaviour in CB1 knockout animals. These data demonstrate at the behavioural level that AM-251 and, at low concentrations, WIN-55,212-2, are selective ligands of the CB1 cannabinoid receptor in mice. Our studies on the behavioural effects of the cannabinoid antagonist SR-141716A and the CB1 antagonist AM-251 show that the CB1 and the novel cannabinoid receptor mediate anxiolytic and anxiogenic effects, respectively. This suggests that agonists of the former, or antagonists of the latter, are promising new compounds in the pharmacotherapy of anxiety.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“which in turn give rise to an anxious/depressive phenotype20, 21.”
From Elevated brain cannabinoid CB1 receptor availability in post-traumatic stress disorder: A positron emission tomography study (2013) · cites this paper as [21]
Citations
Cites
Ledent, C. A., Valverde, O., Cossu, G., Petitet, F., Aubert, J.-F., Beslot, F., Böhme, G. A., Impérato, A., Pedrazzini, T., Roques, B. P., et al. (1999) · Science · doi:10.1126/science.283.5400.401 · Cited by 3,628
Self-citationCannabinoid receptor localization in brain.
Herkenham, M., Lynn, A. B., Little, M. D., Johnson, M. R., Melvin, L. S., de Costa, B. R., & Rice, K. C. (1990) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.87.5.1932 · Cited by 2,321
Endogenous cannabinoids mediate retrograde signalling at hippocampal synapses
Wilson, R. I., & Nicoll, R. A. (2001) · Nature · doi:10.1038/35069076 · Cited by 1,607
Modulation of anxiety through blockade of anandamide hydrolysis
Kathuria, S., Gaetani, S., Fegley, D., Valiño, F., Duranti, A., Tontini, A., Mor, M., Tarzia, G., Rana, G. L., Calignano, A., et al. (2003) · Nature Medicine · doi:10.1038/nm803 · Cited by 1,293
Katona, I., Sperlágh, B., Sı́k, A., Käfalvi, A., Vizi, E. S., Mackie, K., & Freund, T. F. (1999) · The Journal of Neuroscience · doi:10.1523/jneurosci.19-11-04544.1999 · Cited by 1,218
Self-citationA review of the validity and variability of the Elevated Plus-Maze as an animal model of anxiety
Hogg, S. (1996) · Pharmacology Biochemistry and Behavior · doi:10.1016/0091-3057(95)02126-4 · Cited by 1,169
Increased mortality, hypoactivity, and hypoalgesia in cannabinoid CB1 receptor knockout mice
Zimmer, A., Zimmer, A. M., Hohmann, A. G., Herkenham, M. A., & Bonner, T. I. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.10.5780 · Cited by 1,078
The neurobiology and control of anxious states
Millan, M. J. (2003) · Progress in Neurobiology · doi:10.1016/s0301-0082(03)00087-x · Cited by 978
Molecular and neuronal substrate for the selective attenuation of anxiety
Löw, K., Crestani, F., Keist, R., Benke, D., Brünig, I., Benson, J. A., Fritschy, J.-M., Rülicke, T., Bluethmann, H., Möhler, H., et al. (2000) · Science · doi:10.1126/science.290.5489.131 · Cited by 946
Katona, I., Rancz, E. A., Acsády, L., Ledent, C., Mackie, K., Hájos, N., & Freund, T. F. (2001) · The Journal of Neuroscience · doi:10.1523/jneurosci.21-23-09506.2001 · Cited by 668
Interneuron Diversity series: Rhythm and mood in perisomatic inhibition
Freund, T. F. (2003) · Trends in Neurosciences · doi:10.1016/s0166-2236(03)00227-3 · Cited by 641
Self-citationJárai, Z., Wagner, J. A., Varga, K., Lake, K. D., Compton, D. M., Martin, B. R., Zimmer, A. M., Bonner, T. I., Buckley, N. E., Mezey, É., et al. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.24.14136 · Cited by 597
Evidence for a New G Protein-Coupled Cannabinoid Receptor in Mouse Brain
Breivogel, C. S., Griffin, G., Marzo, V. D., & Martin, B. R. (2001) · Molecular Pharmacology · doi:10.1124/mol.60.1.155 · Cited by 538
Involvement of CB1 cannabinoid receptors in emotional behaviour
Martín, M., Ledent, C. A., Parmentier, M., Maldonado, R. J., & Valverde, O. (2002) · Psychopharmacology · doi:10.1007/s00213-001-0946-5 · Cited by 525
Self-citationHájos, N., Ledent, C. A., & Freund, T. F. (2001) · Neuroscience · doi:10.1016/s0306-4522(01)00287-1 · Cited by 421
Self-citationPostsynaptic spike firing reduces synaptic GABAA responses in hippocampal pyramidal cells
Pitler, T. A., & Alger, B. (1992) · Journal of Neuroscience · doi:10.1523/jneurosci.12-10-04122.1992 · Cited by 414
Marzo, V. D., Breivogel, C. S., Tao, Q., Bridgen, D. T., Razdan, R. K., Zimmer, A. M., Zimmer, A., & Martin, B. R. (2000) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2000.0752434.x · Cited by 394
Morales, M., & Bloom, F. E. (1997) · Journal of Neuroscience · doi:10.1523/jneurosci.17-09-03157.1997 · Cited by 364
The effects of genetic and pharmacological blockade of the CB1 cannabinoid receptor on anxiety
Haller, J., Bakos, N., Szirmay, M., Ledent, C., & Freund, T. F. (2002) · European Journal of Neuroscience · doi:10.1046/j.1460-9568.2002.02192.x · Cited by 354
Self-citationThe therapeutic potential of cannabis
Baker, D., Pryce, G., Giovannoni, G., & Thompson, A. J. (2003) · The Lancet Neurology · doi:10.1016/s1474-4422(03)00381-8 · Cited by 350
Navarro, M., Hernández, E., Muñoz, R. M., del Arco, I., Villanúa, M. Á., Carrera, M. R. A., & de Fonseca, F. R. (1997) · Neuroreport · doi:10.1097/00001756-199701200-00023 · Cited by 306
Influence of social isolation, gender, strain, and prior novelty on plus-maze behaviour in mice
Rodgers, R. J., & Cole, J. C. (1993) · Physiology & Behavior · doi:10.1016/0031-9384(93)90084-s · Cited by 294
The psychopharmacology of 5-HT3 receptors
Costall, B., Naylor, R. J., & Tyers, M. B. (1990) · Pharmacology & Therapeutics · doi:10.1016/0163-7258(90)90086-h · Cited by 253
The Role of the Dorsal Hippocampal Serotonergic and Cholinergic Systems in the Modulation of Anxiety
File, S. E., Kenny, P. J., & Cheeta, S. (2000) · Pharmacology Biochemistry and Behavior · doi:10.1016/s0091-3057(00)00198-2 · Cited by 239
Crawley, J. N., Corwin, R. L., Robinson, J. K., Felder, C. C., Devane, W. A., & Axelrod, J. (1993) · Pharmacology Biochemistry and Behavior · doi:10.1016/0091-3057(93)90230-q · Cited by 236
Hájos, N., & Freund, T. F. (2002) · Neuropharmacology · doi:10.1016/s0028-3908(02)00157-0 · Cited by 201
Self-citationNyíri, G., Freund, T. F., & Somogyi, P. (2001) · European Journal of Neuroscience · doi:10.1046/j.1460-9568.2001.01407.x · Cited by 200
Self-citationHilakivi, L. A., Ota, M., & Lister, R. G. (1989) · Pharmacology Biochemistry and Behavior · doi:10.1016/0091-3057(89)90516-9 · Cited by 137
Pistis, M., Perra, S., Pillolla, G., Melis, M., Gessa, G., & Muntoni, A. (2004) · Neuropharmacology · doi:10.1016/j.neuropharm.2003.08.003 · Cited by 124
Ferrari, P. F., Palanza, P., Parmigiani, S., & Rodgers, R. J. (1998) · Physiology & Behavior · doi:10.1016/s0031-9384(97)00544-1 · Cited by 124
Anandamide hydrolysis: a new target for anti-anxiety drugs?
Gaetani, S., Cuomo, V., & Piomelli, D. (2003) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2003.09.005 · Cited by 104
Anxiolytic effects of CCK-B antagonists
Costall, B., Domeney, A. M., Hughes, J. W., Kelly, M. E., Naylor, R. J., & Woodruff, G. N. (1991) · Neuropeptides · doi:10.1016/0143-4179(91)90084-v · Cited by 101
The cannabinoid system: a role in both the homeostatic and hedonic control of eating?
Harrold, J. A., & Williams, G. (2003) · British Journal Of Nutrition · doi:10.1079/bjn2003942 · Cited by 100
Major biological actions of CCK - a critical evaluation of research findings
Fink, H., Rex, A., Voits, M., & Voigt, J. (1998) · Experimental Brain Research · doi:10.1007/s002210050546 · Cited by 88
The Central 5-HT3 Receptor in CNS Disorders
Bloom, F. E., & Morales, M. (1998) · Neurochemical Research · doi:10.1023/a:1022486705184 · Cited by 87
Non-nicotinic neuropharmacological strategies for nicotine dependence: beyond bupropion
Cryan, J. F., Gasparini, F., Heeke, G. V., & Markou, A. (2003) · Drug Discovery Today · doi:10.1016/s1359-6446(03)02890-3 · Cited by 77
Neurobehavioral effects of Δ9-THC and cannabinoid (CB1) receptor gene expression in mice
Onaivi, E. S., Chakrabarti, A., Gwebu, E. T., & Chaudhuri, G. (1995) · Behavioural Brain Research · doi:10.1016/0166-4328(96)00139-8 · Cited by 75
Köfalvi, A., Vizi, E. S., Ledent, C. A., & Sperlágh, B. (2003) · European Journal of Neuroscience · doi:10.1046/j.1460-9568.2003.02897.x · Cited by 70
Self-citationIn-Vitro and In-Vivo Action of Cannabinoids
Akinshola, B. E., Chakrabarti, A., & Onaivi, E. S. (1999) · Neurochemical Research · doi:10.1023/a:1020968922151 · Cited by 66
Effects of intra-hippocampal infusion of WAY-100635 on plus-maze behavior in mice
Nunes‐de‐Souza, R. L., Canto‐de‐Souza, A., & Rodgers, R. J. (2002) · Brain Research · doi:10.1016/s0006-8993(01)03335-2 · Cited by 56
Papp, E., Hájos, N., Acsády, L., & Freund, T. F. (1999) · Neuroscience · doi:10.1016/s0306-4522(98)00455-2 · Cited by 56
Self-citationThe Endocannabinoid System and Huntingtons Disease
Lastres‐Becker, I., Miguel, R., & Fernández‐Ruíz, J. (2003) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/1568007033482751 · Cited by 54
[General Articles] Cannabinoids: Mechanisms and Therapeutic Applications in the CNS
Drysdale, A. J., & Platt, B. (2003) · Current Medicinal Chemistry · doi:10.2174/0929867033456387 · Cited by 51
Karyotype and intermale aggression in wild house mice: Ecology and speciation
Capanna, E., Corti, M., Mainardi, D., Parmigiani, S., & Brain, P. F. (1984) · Behavior Genetics · doi:10.1007/bf01065541 · Cited by 40
Pharmacological and molecular targets in the search for novel antipsychotics
Scatton, B., & Sanger, D. J. (2000) · Behavioural Pharmacology · doi:10.1097/00008877-200006000-00008 · Cited by 39
Cannabinoids and Neuropathic Pain
Goya, P., Jagerovic, N., Hernández‐Folgado, L., & Martín, M. (2003) · Mini-Reviews in Medicinal Chemistry · doi:10.2174/1389557033487818 · Cited by 32
Mauler, F., Horváth, E., Vry, J. D., Jäger, R., Schwarz, T., Sandmann, S., Weinz, C., Heinig, R., & Böttcher, M. (2003) · CNS Drug Reviews · doi:10.1111/j.1527-3458.2003.tb00259.x · Cited by 32
THE INTEGRITY OF THE SOCIAL HIERARCHY IN MICE FOLLOWING ADMINISTRATION OF PSYCHOTROPIC DRUGS
Poshivalov, V. P. (1980) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.1980.tb08712.x · Cited by 23
Cited by
Sorted by citations
The Endocannabinoid System as an Emerging Target of Pharmacotherapy
Pacher, P., Bátkai, S., & Kunos, G. (2006) · Pharmacological Reviews · doi:10.1124/pr.58.3.2 · Cited by 2,077
“Although several hypotheses have been proposed to explain the biphasic effects of cannabinoids on anxiety, including distinct receptors (Haller et al., 2004a,b) or neuroanatomically separated CB1 receptors with a differential sensitivity to the anxiolytic versus anxiogenic effects of cannabinoids,…”
BackgroundNew approaches to antidepressant drug discovery: beyond monoamines
Berton, O., & Nestler, E. J. (2006) · Nature Reviews Neuroscience · doi:10.1038/nrn1846 · Cited by 1,589
Gobbi, G., Bambico, F. R., Mangieri, R. A., Bortolato, M., Campolongo, P., Solinas, M., Cassano, T., Morgese, M. G., Debonnel, G., Duranti, A., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0509591102 · Cited by 692
Neurobiological Interactions Between Stress and the Endocannabinoid System
Morena, M., Patel, S., Bains, J. S., & Hill, M. N. (2015) · Neuropsychopharmacology · doi:10.1038/npp.2015.166 · Cited by 698
“For example, while pharmacological or genetic disruption of CB1 receptor signaling can moderately increase anxiety under basal conditions (Haller et al, 2002, 2004; Hill et al, 2011a; Martin et al, 2002; Mikics et al, 2009; Uriguen et al, 2004), this manipulation dramatically enhances anxiety…”
Background50 years of hurdles and hope in anxiolytic drug discovery
Griebel, G., & Holmes, A. (2013) · Nature Reviews Drug Discovery · doi:10.1038/nrd4075 · Cited by 430
Metadata
- Authors
- Haller, J., Varga, B., Ledent, C., & Freund, T. F.
- Affiliations
- HUN-REN Institute of Experimental Medicine (HU)
- Université Libre de Bruxelles (BE)
- Corresponding author
- Haller, J.
- Venue
- Behavioural Pharmacology
- Published
- 2004-07
- Volume
- 15
- Issue
- 4
- Pages
- 299-304
- ISSN
- 0955-8810 (ISSN-L)
- OpenAlex
- W2009732294
- Cited by
- 241
- References
- 49
- Citations by year
- 2026: 3 · 2025: 12 · 2024: 4 · 2023: 12 · 2022: 5 · 2021: 9 · 2020: 8 · 2019: 7 · 2018: 8 · 2017: 7 · 2016: 6 · 2015: 9 · 2014: 9 · 2013: 13 · 2012: 15
- FWCI
- 8.79
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Behavioural Pharmacology (publishedVersion)
- PubMed (publishedVersion)
- Dépôt institutionnel de l'Université libre de Bruxelles (Université Libre de Bruxelles) (submittedVersion)
- Funders
- National Institute of Mental Health (R01MH054671, MH54671)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Cannabis and Cannabinoid Research
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
- Keywords
- CB1 receptor, anxiolytic effects, anxiety-like behavior, CB1 knockout mice, AM251, WIN 55,212-2, SR141716A, CB1 agonists, elevated plus maze, GABAergic neurotransmission, glutamatergic neurotransmission
- MeSH terms
- Rimonabant, Animals, Behavior, Animal, Dose-Response Relationship, Drug, Drug Synergism, Male, Morpholines, Naphthalenes, Piperidines, Pyrazoles, Anti-Anxiety Agents, Mice, Knockout, Maze Learning, Receptor, Cannabinoid, CB1, Benzoxazines, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
